Drugs / nal-irinotecan
nal-irinotecan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04617457 | Oct 2021 → Dec 2024 | malignant pancreatic neoplasm, metastatic neoplasm | University of Cologne | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nal-irinotecan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04617457 ↗ |
| Known as | nal-irinotecan (nal-iri) | “nal-irinotecan (nal-iri)” NCT04617457 ↗ |
| Known as | Onyvide | “nal-irinotecan (nal-iri) (Onyvide), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA)” NCT04617457 ↗ |